Roche Launches New MagNA Pure 96 System: A Perfect Combination of Performance and High Throughput

The new MagNA Pure 96 System from Roche Applied Science (Pink Sheets:RHHBY) (SWX:RO) (SWX:ROG) has been designed and engineered to meet the needs for high throughput laboratories worldwide. Its performance is based on Roche Applied Science’s 10 years experience in the development and application of glass-magnetic-particle based automated nucleic acid purification systems.

The new automated system provides rapid sample processing for increased productivity. The integrated system enables batch processing of up to 96 samples in parallel ensuring every sample is treated exactly the same while providing extremely quick turnaround time. These characteristics result in a low sample processing time; for typical standard applications, 96 samples can be completely processed with the fully automated MagNA Pure 96 System in less than one hour, including instrument setup. Additionally, prefilled reagent kits and disposables from Roche enable a convenient, safe, and fast setup of purification runs.

The new MagNA Pure 96 System offers a broad field of applications, including isolation of DNA, RNA, and viral nucleic acid. It can be used with various research sample materials such as mammalian whole blood, cells, plasma, serum, PAXgene tubes, or tissue. Sample input volumes range from 50–1000 μl to enable maximum flexibility in respect to the individual needs of yield and sensitivity. The data management is facilitated by the flexible connectivity features, with an optimized data workflow, when used in combination with the LightCycler® 480 System. With the launch of this innovative purification system, Roche is ready to ship the first 20 MagNA Pure 96 Systems in October.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

MAGNA PURE and LIGHTCYCLER are trademarks of Roche.

All trademarks used or mentioned in this release are protected by law.